| 摘要 |
PROBLEM TO BE SOLVED: To provide an afucosylated anti-CD20 antibody used in combination therapy with an anti-VEGF antibody, for the treatment of a CD20 expressing cancer such as a B-Cell Non-Hodgkin's lymphoma (NHL), and provide the combination therapy.SOLUTION: The afucosylated anti-CD20 antibody is an afucosylated anti-CD20 antibody with an amount of fucose of 60% or less of the total amount of oligosaccharides (sugars) at Asn297, particularly a humanized B-Ly1 antibody. The anti-VEGF antibody is bevacizumab, a B20 series antibody or G6 series antibody. |
